TRDA
Entrada TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The company did deliver favorable safety, no serious adverse events, normal kidney markers, and a statistically significant Time to Rise velocity signal in Cohort 1, while management argues the pediatric PK shortfall is now better understood and can be addressed with higher dosing in Cohort 2 [#8-K-2026-05-07]. If that explanation holds, the May 7 selloff may have overshot the remaining platform option value.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -2.3.
What can break
Cash runway extends only into Q3 2027, while Q1 2026 net loss was $39.7 million and collaboration revenue fell sharply year over year, so any meaningful delay or weak follow-up data could revive financing risk [#8-K-2026-05-07].
Momentum
1
Value
58
Sentiment
59
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.50 · Bull $11.00 · Bear $4.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $20.00
Why
Momentum1 · Δ7d -0.1
Value58 · Δ7d +0.4
Sentiment59 · Δ7d -2.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
1
34% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-10.1
Value
58
32% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+0.1
Sentiment
59
33% active weight
Current posture
7d trendSoftening
Δ7d
-2.3
Δ21d
+9.5
Why this grade
Composite grade F. Momentum 1.4 / Value 58.0 / Sentiment 59.3
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$268.25M
Beta
-0.12
Shares Out
38.22M
P/E (TTM) · Derived
-2.0
P/S (TTM)
6.52
P/FCF (TTM) · Derived
-2.26
Rev YoY
-91.8%
EPS YoY
-208.2%
Gross Margin
-
Op Margin
-197.6%
Net Debt
-$420M
Current Ratio
14.08
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology